Merck Gains CHMP Positive Opinion for KEYTRUDA Combo in Bladder Cancer Indication

A CHMP positive opinion for Merck's KEYTRUDA (pembrolizumab) in combination therapy for bladder cancer now positions the European Commission to issue a formal marketing authorisation decision, with a ruling anticipated in Q3 2026. For regulatory affairs leads managing EU market access timelines, the opinion marks the point at which label finalisation, distribution planning, and post-authorisation commitments move from contingency to active workstreams.

The Committee for Medicinal Products for Human Use issued the positive opinion following its standard scientific review process under the centralised procedure. Under EU regulatory framework, a CHMP positive opinion is not itself a marketing authorisation; the European Commission retains the formal decision-making authority and typically converts CHMP recommendations into binding approvals within 67 days. That procedural interval sets the Q3 2026 window cited in the decision timeline.

For oncology portfolio teams and QA directors at sites supplying the European market, the interval between CHMP opinion and EC decision is operationally significant. Batch release protocols, qualified person oversight, and any required risk management plan updates must be aligned before the authorisation date, not after. Sites already holding EU GMP certification for pembrolizumab manufacture will need to confirm that any combination-product labelling changes are reflected in their quality management systems ahead of commercial launch.

KEYTRUDA's existing EU authorisations across multiple oncology indications mean Merck's regulatory infrastructure for this market is established, but each new indication carries its own post-authorisation obligations, including periodic safety update report schedules and any indication-specific pharmacovigilance requirements agreed during the CHMP review.

Market access leads in EU member states will be tracking the EC decision date closely, as national reimbursement negotiations in major markets typically cannot formally commence until the Commission authorisation is published in the Official Journal of the European Union.

The Q3 2026 EC decision date will serve as the baseline from which post-authorisation safety study timelines and first PSUR submission windows are calculated.

Source: Media4Growth via Indian Pharma Post, 24 May 2026.